By building a pipeline of gamma secretase inhibitors (GSIs) with broad yet targeted clinical utility, we aim to serve patient populations in need of better therapies. Our investigational product candidates have been, and are currently still being, evaluated in clinical trials at leading oncology centers across the United States, Europe and Canada.